Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Alair study: Long-term efficacy of Asthmatx's bronchial thermoplasty system is demonstrated by five-year data from the Asthma Intervention Research (AIR) trial, presented May 19 at the American Thoracic Society annual meeting in New Orleans. Results showed that over five years, the percentage of patients reporting respiratory adverse events remained stable; hospitalizations and ER visits for respiratory symptoms remained stable; pulmonary function remained stable; and there were no incidences of pneumothorax, intubation, mechanical ventilation, cardiac arrhythmias or death as a result of treatment with Alair. The system, which delivers thermal energy to reduce excess airway smooth muscle associated with airway constriction, is the first device-based asthma treatment approved by FDA (1"The Gray Sheet" May 3, 2010)

You may also be interested in...



Asthmatx Debuts Alair For Severe Asthma Following PMA Approval

Asthmatx is initiating a "focused launch" of its Alair bronchial thermoplasty system after receiving PMA approval April 27, according to CEO Glen French

Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

Topics

UsernamePublicRestriction

Register

MT028923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel